VYNE Therapeutics's total assets for Q2 2025 were $44.72M, a decrease of -20.75% from the previous quarter. VYNE total liabilities were $5.84M for the fiscal quarter, a -52.52% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.